A biobank of reversible mutant embryonic stem cells – Phys.Org
Phys.Org |
A biobank of reversible mutant embryonic stem cells
Phys.Org Scientist at IMBA developed a biobank of revertible, mutant embryonic stem cells, published in the current issue of Nature. This cell bank – called Haplobank – contains over 100,000 mutated, conditional mouse embryonic stem cell lines, targeting about … |
The Guardian |
‘Chemical surgery’ used to mend harmful mutations in human embryos
The Guardian In the past decade, scientists have developed a range of powerful tools to edit the genetic code, the most popular of which is called Crispr-Cas9. The method uses enzymes to make precision cuts in faulty genes which the body can then repair with the … DNA surgery on embryos removes diseaseBBC News New gene editor used to fix disease in embryos: studyPhys.Org Incredibly, Scientists Have Cured An Embryo Of A Life-Threatening Disease By Altering Its DNAHuffPost UK IFLScience –Telegraph.co.uk –Week Facts all 17 news articles » |
The Guardian |
‘Chemical surgery’ used to mend harmful mutations in human embryos
The Guardian In the past decade, scientists have developed a range of powerful tools to edit the genetic code, the most popular of which is called Crispr-Cas9. The method uses enzymes to make precision cuts in faulty genes which the body can then repair with the … DNA surgery on embryos removes diseaseBBC News New gene editor used to fix disease in embryos: studyPhys.Org Incredibly, Scientists Have Cured An Embryo Of A Life-Threatening Disease By Altering Its DNAHuffPost UK IFLScience –Telegraph.co.uk –Week Facts all 17 news articles » |
Imperial College London |
Japanese collaborations reach new heights
Imperial College London The 2nd Tokyo Tech-Imperial Workshop, brought together some of the world’s leading researchers to explore new collaborations in bioscience and its links with technology, encompassing expertise in synthetic biology, data science and neurotechnology. |
Labiotech.eu (blog) |
Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs
Labiotech.eu (blog) Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing one-shot gene therapies for various eye diseases that … Nightstar Therapeutics (Nasdaq: NITE) to Ring The Nasdaq Stock Market Closing Bell in Celebration of Its IPONasdaq Syncona’s Nightstar reveals details on US IPODIGITALLOOK |